STOCK TITAN

Vincerx Pharma (VINC) Financials

VINC OTC
Trailing 12 months to March 31, 2025
Revenue Not reported for the trailing 12 months
Net Income -$22.6M n/m YoY
EPS (Diluted) -$15.85 FY2024 annual
Operating Cash Flow -$22.8M n/m YoY
Market Cap $79K as of Nov 16, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to March 31, 2025
Price / Book 0.0x on $2.1M equity, Q1 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings Latest period Q1 FY2025, ended Mar 31, 2025 Reported Currency USD FYE December

Newest figures come from the filing for Q1 FY2025, filed May 15, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VINC SEC filings page.

This page shows Vincerx Pharma Inc (VINC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Vincerx Pharma Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Vincerx Pharma Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Vincerx Pharma Inc reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$3.3M
YoYn/m

Vincerx Pharma Inc's EBITDA was -$3.3M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net Income
-$5.0M
YoYn/m
QoQn/m

Vincerx Pharma Inc reported a net loss of $5.0M in Q1 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.40

Vincerx Pharma Inc earned -$1.40 per diluted share (EPS) in Q1 2025.

Revenue

Not reported for Q1 2025.

Cash & Balance Sheet

Cash & Debt
$4.4M
YoY-13.2%
QoQ-11.0%
5Y CAGR+42.7%

Vincerx Pharma Inc held $4.4M in cash as of Q1 2025; no long-term debt figure is on record for that period.

Shares Outstanding
5M
QoQ0.0%

Vincerx Pharma Inc had 5M shares outstanding in Q1 2025. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2025.

Dividends Per Share

Not reported for Q1 2025.

Margins & Returns

Return on Equity
-242.0%
QoQ+51.5pp

Vincerx Pharma Inc's quarterly ROE was -242.0% in Q1 2025: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 51.5 percentage points.

Gross Margin

Not reported for Q1 2025.

Operating Margin

Not reported for Q1 2025.

Net Margin

Not reported for Q1 2025.

Capital Allocation

R&D Spending
$1.0M
YoY-77.7%
QoQ-68.8%

Vincerx Pharma Inc invested $1.0M in research and development in Q1 2025. This represents a decrease of 77.7% from the same quarter a year earlier. Against the prior quarter it is down 68.8%.

Share Buybacks

Not reported for Q1 2025.

Capital Expenditures

Not reported for Q1 2025.

VINC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly income statement
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
R&D Expenses$1.0M-77.7%$3.3M-12.0%$3.9M-35.9%$3.8M-54.5%$4.6M-58.2%$3.7M$6.1M-44.9%$8.2M-40.0%
SG&A Expenses$2.3M-20.7%$5.6M+205.4%$3.9M+10.7%$3.6M-5.2%$2.9M-35.0%$1.8M$3.5M-22.5%$3.8M-19.3%
Operating Income-$3.3Mn/m-$8.8Mn/m-$7.8Mn/m-$7.4Mn/m-$7.5Mn/m-$5.5M-$9.6Mn/m-$12.1Mn/m
EBITDA-$3.3Mn/mN/A-$7.8Mn/m-$7.4Mn/m-$7.5Mn/mN/A-$9.6Mn/m-$12.0Mn/m
Net Income-$5.0Mn/m-$8.0Mn/m-$7.8Mn/m-$1.8Mn/m-$12.4Mn/m-$5.0M-$9.0Mn/m-$11.6Mn/m
EPS (Basic)-$1.40N/A-$3.40-$1.00-$11.46-$4.60n/m-$8.40-$10.80n/m
EPS (Diluted)-$1.40N/A-$15.85-$1.00-$11.46-$4.60n/m-$37.72-$10.80n/m
Diluted Shares (Avg)4MN/A2,2842M1,085N/A1,0671M+1.3%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

VINC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly balance sheet
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Total Assets$4.7M-57.7%$8.0M-56.1%$14.9M-43.1%$21.5M-39.0%$11.1M-76.6%$18.2M-69.3%$26.3M-63.7%$35.3M-59.8%
Current Assets$4.7M-39.0%$6.4M-56.5%$11.7M-48.5%$18.3M-42.5%$7.7M-82.6%$14.7M-73.7%$22.8M-66.1%$31.8M-61.4%
Cash & Equivalents$4.4M-13.2%$5.0M-61.0%$2.9M-80.5%$7.9M+18.6%$5.1M+13.8%$12.8M+9.6%$15.1M-67.1%$6.7M-91.7%
Short-Term Investments$0n/m$0n/m$7.1M+24.8%$8.4M-59.4%$0-100.0%$0-100.0%$5.7M-71.6%$20.7Mn/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$2.6M-77.6%$5.3M-24.5%$5.8M-44.6%$6.1M-45.4%$11.7M-9.8%$7.0M-39.8%$10.5M-16.8%$11.1M-16.8%
Current Liabilities$2.6M-75.4%$5.3M-5.8%$5.4M-38.7%$5.3M-41.8%$10.6M-0.7%$5.6M-38.8%$8.8M-11.1%$9.2M-12.4%
Non-Current Liabilities$0-100.0%$0-100.0%$415K-75.4%$747K-62.3%$1.1M-52.8%$1.4M-43.5%$1.7M-37.9%$2.0M-32.4%
Total Equity$2.1Mn/m$2.7M-75.7%$9.1M-42.1%$15.4M-36.0%-$622K-101.8%$11.2M-76.5%$15.7M-73.6%$24.1M-67.5%
Retained Earnings-$194.2Mn/m-$189.2Mn/m-$181.2Mn/m-$173.3Mn/m-$171.5Mn/m-$159.1Mn/m-$156.5Mn/m-$146.8Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

VINC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly cash flow statement
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Operating Cash Flow-$4.5Mn/m-$6.2Mn/m-$6.4Mn/m-$5.8Mn/m-$7.7Mn/m-$8.0Mn/m-$6.6Mn/m-$12.7Mn/m
Depreciation & Amortization$0-100.0%$13K+8.3%$13K-7.1%$13K0.0%$13K0.0%$12K-14.3%$14K+7.7%$13K0.0%
Stock-Based Compensation$435K-17.6%N/A$1.4M+126.2%$912K-16.6%$528K-61.8%N/A$629K-72.5%$1.1M-67.5%
Investing Cash FlowN/A$7.2M+24.8%$1.4M-90.9%-$8.3M-156.3%$0-100.0%$5.8Mn/m$15.1Mn/m$14.8Mn/m
Financing Cash Flow$3.9M+77020.0%$985K+5372.2%$0n/m$17.0M+18181.7%$5K+66.7%$18K-52.6%$0n/m$93K-61.6%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

VINC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly financial ratios
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Return on Equity-242.0%-293.5%-249.4pp-86.1%-28.9pp-11.7%+36.1ppN/A-44.1%-57.2%-29.0pp-47.9%-23.1pp
Return on Assets-106.7%+5.4pp-99.9%-72.7pp-52.5%-18.2pp-8.4%+24.3pp-112.1%-81.3pp-27.2%-34.3%-11.0pp-32.7%-11.8pp
Current Ratio1.79+1.1x1.21-1.4x2.17-0.4x3.430.0x0.72-3.4x2.63-3.5x2.58-4.2x3.47-4.4x
Liabilities-to-Equity1.271.94+1.3x0.640.0x0.39-0.1xN/A0.62+0.4x0.67+0.5x0.46+0.3x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Vincerx Pharma Inc VINC FY2024 N/A -$30.1M N/A $79K —
Sigyn Therapeutics Inc SIGY FY2024 N/A N/A N/A $145K —
CERo Terapeutics Holding Inc CERO FY2025 N/A N/A N/A $217K —
Regen BioPharma Inc RGBP FY2025 $237K -$1.3M N/A $355K —
Carisma Therapeutics Inc CARM FY2024 $19.6M -$60.5M N/A $8K —
Lyra Therapeutics Inc LYRA FY2025 $398K -$28.9M N/A $337K —

Frequently Asked Questions

No, Vincerx Pharma Inc (VINC) reported a net loss of $22.6M over the trailing 12 months to March 31, 2025. In fiscal year 2024 it reported a net loss of $30.1M.

Vincerx Pharma Inc (VINC) reported diluted earnings per share of -$15.85 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vincerx Pharma Inc (VINC) had EBITDA of -$31.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Vincerx Pharma Inc (VINC) has a return on equity of -1104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

Vincerx Pharma Inc (VINC) recorded an outflow of $26.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

Vincerx Pharma Inc (VINC) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.

Vincerx Pharma Inc (VINC) invested $15.5M in research and development during fiscal year 2024.

Vincerx Pharma Inc (VINC) had 5M shares outstanding as of fiscal year 2024.

Vincerx Pharma Inc (VINC) had a current ratio of 1.21 as of fiscal year 2024, which is considered adequate.

Vincerx Pharma Inc (VINC) had a liabilities-to-equity ratio of 1.94 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.

Vincerx Pharma Inc (VINC) had a return on assets of -375.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Vincerx Pharma Inc (VINC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2025). The market capitalization is $79K as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Vincerx Pharma Inc (VINC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $79K as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2024, Vincerx Pharma Inc (VINC) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Vincerx Pharma Inc (VINC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Vincerx Pharma Inc (VINC) reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top